PP
REGN icon

Pacifica Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Pacifica Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.7K Hold
20
– – ﹤0.01% 262
2026
Q2 		$13.1K Hold
20
– – ﹤0.01% 287
2026
Q1 		$15.5K Hold
20
– – 0.01% 278
2025
Q4 		$15.5K Buy
20
+10
+100% +$6.79K 0.01% 265
2025
Q3 		$6K Hold
10
– – ﹤0.01% 375
2025
Q2 		$5.21K Hold
10
– – ﹤0.01% 392
2025
Q1 		$6.11K Hold
10
– – ﹤0.01% 373
2024
Q4 		$7.15K Buy
+10
New +$8.39K ﹤0.01% 352

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Pacifica Partners's REGN Position: Q3 2026 in Review

Pacifica Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 20 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

Pacifica Partners first reported a position in REGN in Q4 2024 and has held it in 8 quarters since. The position peaked at $15.5K in Q4 2025. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Pacifica Partners held 20 shares of Regeneron Pharmaceuticals worth $14.7K as of Q3 2026.
  • Pacifica Partners left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Pacifica Partners's portfolio in Q3 2026, its #262 holding.
  • Pacifica Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • Pacifica Partners's Regeneron Pharmaceuticals position peaked at $15.5K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Pacifica Partners's 13F filing for Q3 2026, filed 9 Oct 2026.